welcome
Reuters

Reuters

Health

Health

Drugmaker Biogen forecasts 2025 profit below expectations

Reuters
Summary
Nutrition label

82% Informative

Biogen stock fell 3% in pre-market trading on Wednesday .

Investors sold Biogen shares in 2024 as a slow US launch of Leqembi , the Alzheimer's disease drug it sells with Japan 's Eisai , exacerbated worries of slowing sales growth.

Biogen expects 2025 revenue to decline by a mid-single digit percentage, excluding the impact of currency fluctuations.

VR Score

93

Informative language

98

Neutral language

89

Article tone

formal

Language

English

Language complexity

48

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links